Obesity
|
0.240 |
GeneticVariation
|
disease |
BEFREE |
Further validation in cohorts with severe obesity and engineering the variants in model organisms will be needed to explore whether human variants in ANGPTL6 and other genes that lead to obesity when deleted in mice, do contribute to obesity.
|
28663568 |
2017 |
Thyroid stimulating hormone measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A genome-wide association study identifies protein quantitative trait loci (pQTLs).
|
18464913 |
2008 |
Intracranial Aneurysm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Altogether, our results indicate that rare coding variants in ANGPTL6 are causally related to familial forms of IA.
|
29304371 |
2018 |
Obesity, Morbid
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Further validation in cohorts with severe obesity and engineering the variants in model organisms will be needed to explore whether human variants in ANGPTL6 and other genes that lead to obesity when deleted in mice, do contribute to obesity.
|
28663568 |
2017 |
Familial (FPAH)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Rare Coding Variants in ANGPTL6 Are Associated with Familial Forms of Intracranial Aneurysm.
|
29304371 |
2018 |
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
Obesity
|
0.240 |
Biomarker
|
disease |
MGD |
This study establishes AGF as a new hepatocyte-derived circulating factor that counteracts obesity and related insulin resistance.
|
15778720 |
2005 |
Obesity
|
0.240 |
Biomarker
|
disease |
BEFREE |
Specially, bANGPTL6β gene probably contributes to a new target for treatment of obesity and obesity-related diseases.
|
31102716 |
2019 |
Hypertensive disease
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
Hypertensive disease
|
0.110 |
Biomarker
|
group |
BEFREE |
We observed a higher rate of individuals with a history of high blood pressure among affected versus healthy individuals carrying ANGPTL6 variants, suggesting that ANGPTL6 could trigger cerebrovascular lesions when combined with other risk factors such as hypertension.
|
29304371 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Transient Ischemic Attack
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Encephalomalacia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hemiparesis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Oculomotor Nerve Paralysis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Seizures
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Subarachnoid Hemorrhage
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dissection of aorta
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Aneurysm of aortic root
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormality of brainstem morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Saccular Aneurysm
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Visual field defects
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Abnormal circle of Willis morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
AGF support tumor growth and progression.
|
27419371 |
2017 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
ANGPTL6 loss results in tumor growth in vivo.
|
31146977 |
2019 |